Health-related quality of life as outcome parameter in haemophilia treatment

被引:61
作者
Fischer, K
Van der Bom, JG
Van den Berg, HM
机构
[1] Univ Med Ctr Utrecht, Dept Paediat, NL-3508 AB Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Van Creveldklin, NL-3508 AB Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Julius Ctr Gen Practice & Patient Oriented Res, NL-3508 AB Utrecht, Netherlands
关键词
EQ-5D; health-related quality of life; outcome; SF-36; utility;
D O I
10.1046/j.1365-2516.9.s1.13.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Health-related quality of life (HRQoL) is increasingly used as an outcome parameter in haemophilia treatment. Currently, only generic HRQoL instruments are used, as disease-specific instruments for haemophilia are not available. The most widely used generic instruments are the descriptive SF-36 questionnaire and the EQ-5D questionnaire for assessment of utilities, ie preference-based HRQoL. Results of both instruments show significant correlation. All haemophilia prophylaxis studies using HRQoL as an outcome report a decreased HRQoL compared with the general population, a positive effect of prophylactic treatment and a negative effect of age. Generic instruments for measuring HRQoL are able to pick up differences between groups of patients with haemophilia and enable us to make comparisons across diseases. However, in order to establish the optimal treatment strategy for severe haemophilia, further information is needed on the long-term effects of different strategies on HRQoL. In addition, haemophilia-specific HRQoL instruments should be developed in order to provide detailed information for adjustment and evaluation of treatment in individual patients.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 42 条
[1]   Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations [J].
Aaronson, NK ;
Muller, M ;
Cohen, PDA ;
Essink-Bot, ML ;
Fekkes, M ;
Sanderman, R ;
Sprangers, MAG ;
Velde, AT ;
Verrips, E .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1055-1068
[2]   The orthopaedic status of severe haemophiliacs in Spain [J].
Aznar, JA ;
Magallón, M ;
Querol, F ;
Gorina, E ;
Tusell, JM .
HAEMOPHILIA, 2000, 6 (03) :170-176
[3]   HEALTH-RELATED UTILITY MEASUREMENT IN RHEUMATOLOGY - AN INTRODUCTION [J].
BAKKER, CH ;
RUTTENVANMOLKEN, M ;
VANDOORSLAER, E ;
BENNETT, K ;
VANDERLINDEN, S .
PATIENT EDUCATION AND COUNSELING, 1993, 20 (2-3) :145-152
[4]  
Bellamy N., 1988, J ORTHOP RHEUMATOL, V1, P95
[5]   The estimation of a preference-based measure of health from the SF-36 [J].
Brazier, J ;
Roberts, J ;
Deverill, M .
JOURNAL OF HEALTH ECONOMICS, 2002, 21 (02) :271-292
[6]   Pilot testing of the 'Haemo-QoL' quality of life questionnaire for haemophiliac children in six European countries [J].
Bullinger, M ;
von Mackensen, S ;
Fischer, K ;
Khair, K ;
Petersen, C ;
Ravens-Sieberer, U ;
Rocino, A ;
Sagnier, P ;
Tusell, JM ;
van den Berg, M ;
Vicariot, M .
HAEMOPHILIA, 2002, 8 :47-54
[7]  
Cella D F, 1990, Oncology (Williston Park), V4, P29
[8]   A comparative review of generic quality-of-life instruments [J].
Coons, SJ ;
Rao, S ;
Keininger, DL ;
Hays, RD .
PHARMACOECONOMICS, 2000, 17 (01) :13-35
[9]  
Djulbegovic B, 1996, HAEMOPHILIA, V2, P166, DOI 10.1111/j.1365-2516.1996.tb00161.x
[10]   Cost-utility analysis of recombinant factor VIIa (NovoSeven®) in six children with long-standing inhibitors to factor VIII or IX [J].
Ekert, H ;
Brewin, T ;
Boey, W ;
Davey, P ;
Tilden, D .
HAEMOPHILIA, 2001, 7 (03) :279-285